Ozempic and Wegovy for Weight Loss, Pharmacological Component and Effect

Abstract

In the USA, the obesity pandemic is becoming worse. The development of non-invasive pharmacotherapeutics to assist treat obesity is of tremendous interest because gaining weight is linked to an increased risk of developing life-threatening comorbidities, such as type 2 diabetes or hypertension. Numerous approaches have been used to control obesity, including dietary modifications, the use of appetite suppressants and thermogenic medications, and bariatric surgery for those who are extremely fat. Two of the five anti-obesity medications that have received FDA approval are Ozempic and Wegovy. These medications are intended to treat individuals with type 2 diabetes mellitus (T2DM). Researchers examined the weight loss effects of T2DM therapies that have shown weight loss results in this study by assessing existing clinical studies for each agent in order to emphasize the beneficial effects of these medications as anti-obesity therapy. Numerous clinical investigations have demonstrated that whereas certain antihyperglycemic drugs induce weight gain or have neutral effects, others can aid in weight loss. A class of anti-diabetic drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists has demonstrated promise in glycemic control and weight loss in individuals with or without type 2 diabetes.